Kicking off the Mexican Guidelines meeting with IBCG team
Energizing to see such strong engagement and enthusiasm as we work together to shape evidence-based standards for bladder cancer care in Mexico
#BladderCancer#GlobalOncology@IBCG_BladderCA
When testicular cancer is found early, in Stage 1, 99% of patients are cured after treatment. Remember to self-check regularly and talk to your doctor if you have any concerns.
Join this 5 km social run to raise money for a @AFUrologie research project to investigate the positive effects of physical activity for prostate cancer patients.
#ProstateCancer#EAU24@BAUSurology
🌟 Following the #RESECT buzz, the stage is set for #EAU24!
✨ Come join @kmj_gallagher as he reveals the largest #TURBT study results from #RESECT 👀
🤔 Where and when?
📅 SUN 7 APR | 🕔 17:15 - 18:45
📍 Purple Area, S03, Abstract Session 36
🔢 Abstract # | A0730
#UroSoMe
💡 Focused on improving #TURBT, @veerukasi sheds light on #RESECT’s innovative study design! 🤯
🗓️ Be there for the big reveal at our #EAU24 abstract presentation AND the in-depth discussions at our Global Collaborators' Meeting.
👀 Details coming tomorrow…! #UroSoMe
Learn how to perform TURBT for
Large vascular Bladder tumors for Residents ( 17 role not to miss )
12 min Tips & Tricks at YouTube link
https://t.co/pfV8okHO1u
Hello #urologists!
When treating patients with symptomatic BPH do not forget to assess their risk of disease progression.
It might help decide which treatment option is more suited for the patient.
Have a nice week!
#bph#boo#urology
🎉 #RESECT IS COMING TO #𝗔𝗨𝗔24 AND #𝗘𝗔𝗨24
�� Find out if feedback makes a difference to surgical quality and outcomes in #TURBT surgery
🚀 Our presentations are a great teaser for the full paper which is currently in preparation 👀👀
🇫🇷 We look forward to sharing in detail with investigators at collaborators' meeting in Paris!
#UroSoMe
🧵1/12 🔍 Understanding #NMIBC: Key Categories 🧬
🚫 Refractory: High-grade disease persists at 6 months despite BCG therapy. Includes any stage/grade progression by 3 months.
🔄 Relapsing: High-grade recurrence after disease-free state at 6 months post-BCG.
🛑 Intolerant: Inability to complete BCG due to toxicity.
🔴 Unresponsive: Encompasses both BCG refractory and relapsing cases. This high-risk group needs alternatives to BCG. https://t.co/SFZpFr7yY5
#BladderCancer #OncologyCommunity
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2023: Some negative, some positive, but we learned from all!
Feel free to add more & retweet & tag
This is not an exhaustive list!
@OncoAlert@danafarber@DanaFarber_GU#OnwardFor2024
🚨 Emergency #haematuria is among the top urology admissions (more than 15%)! 😮
Yet, we lack solid, evidence-based guidelines on its management… 🤔
...Presenting #WASHOUT!